Evidence map›Paper›PMID 31463563›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2020

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.

Rebecca Schennach, Michael Riedel, Michael Obermeier, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel and 11 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Influence of PsychotropicClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 1 country.

Rebecca SchennachDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany. RSchennach@schoen-kliniken.de.ORCID http://orcid.org/0000-0001-6923-3249
Michael RiedelDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Michael ObermeierDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Markus JägerDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Max SchmaussPsychiatric Clinic, District Hospital Augsburg, Augsburg, Germany.
Gerd LauxPsychiatric Clinic, Inn-Salzach Hospital, Wasserburg/Inn, Germany.
Herbert PfeifferPsychiatric Clinic, Isar-Amper Hospital, Munich-Haar, Germany.
Dieter NaberDepartment of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Germany.
Lutz G SchmidtDepartment of Psychiatry and Psychotherapy, University of Mainz, Mainz, Germany.
Wolfgang GaebelDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
Joachim KlosterkötterDepartment of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.
Isabella HeuserDepartment of Psychiatry and Psychotherapy, Charite Berlin, Campus Benjamin Franklin, Berlin, Germany.
Wolfgang MaierDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
Matthias R LemkeDepartment of Psychiatry, Alsterdorf Hospital, Hamburg, Germany.
Eckart RütherDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
Stefan KlingbergDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
Markus GastparDepartment of Psychiatry and Psychotherapy, University of Essen, Essen, Germany.
Florian SeemüllerDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Ilja SpellmannDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Richard MusilDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Hans-Jürgen MöllerDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Ludwig-Maximilians-Universität München · DECharité - Universitätsmedizin Berlin · DEEvangelisches Krankenhaus Alsterdorf · DEHeinrich Heine University Düsseldorf · DEInn-Salzach-Klinikum · DEIsar-Amper-Klinikum München-Ost · DEJohannes Gutenberg University Mainz · DEKempten University of Applied Sciences · DEKlinikum Stuttgart · DESächsisches Krankenhaus Rodewisch · DESchön Klinik Roseneck · DEUniversität Hamburg · DEUniversity Hospital Augsburg · DEUniversity of Bonn · DEUniversity of Cologne · DEUniversity of Göttingen · DEUniversity of Tübingen · DE

Funding

BMBF Grant 01 GI 0233
6 · The paper itself

Abstract

Aim of the study was to examine the course of schizophrenia patients within 2 years after discharge. Within a multicenter study of the German Competence Network on Schizophrenia, patients suffering from a schizophrenia spectrum disorder were examined regarding their psychopathological improvement, tolerability, and the treatment regime applied during hospitalization and a 2-year follow-up period. Response, remission, the level of everyday functioning, and relapse were furthermore evaluated during the follow-up period using established definitions for these outcome domains. The psychopharmacological treatment was specifically evaluated in terms of a potential association with relapse. 149 patients were available for analysis, with 65% of the patients being in response, 52% in symptomatic remission, and 64% having a satisfiable everyday functioning 2 years after their discharge from hospital. Despite these favorable outcome rates, 63% of the patients suffered from a relapse within the 2-year follow-up period with 86% of these patients being rehospitalized. Discharge non-responder and non-remitter were twice as likely to relapse during follow-up. A significant decrease of side-effects was observed with negligible rates of extrapyramidal side-effects, sedation, and weight gain during follow-up. Patients receiving treatment with atypical antipsychotics were found to have the lowest risk to relapse (p < 0.0001). The results highlight the natural and unsteady course of schizophrenia in most patients underlining the need to develop more specific treatment strategies ensuring ongoing stability and preventing relapse.

Indexed as

Drug MonitoringActivities of Daily LivingAdultAntipsychotic AgentsDisease ProgressionFemaleFollow-Up StudiesGermanyHumansMaleMiddle AgedOutcome Assessment, Health CarePatient DischargePatient ReadmissionPsychotic DisordersRecurrenceAntipsychotic Agents2-year follow-upFunctioningRelapseRemissionResponseSchizophrenia

Identifiers

PMID31463563
OpenAlexW2971318931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.